Patents Assigned to RaNA Therapeutics, Inc.
-
Publication number: 20150232847Abstract: Aspects of the invention relate to methods for increasing gene expression in a targeted manner. In some embodiments, methods and compositions are provided that are useful for posttranscriptionally altering protein and/or RNA levels in a targeted manner. Aspects of the invention disclosed herein provide methods and compositions that are useful for protecting RNAs from degradation (e.g., exonuclease mediated degradation).Type: ApplicationFiled: April 30, 2015Publication date: August 20, 2015Applicant: RaNA Therapeutics, Inc.Inventor: FATIH OZSOLAK
-
Publication number: 20150232845Abstract: Aspects of the invention relate to methods for increasing gene expression in a targeted manner. In some embodiments, methods and compositions are provided that are useful for posttranscriptionally altering protein and/or RNA levels in a targeted manner. Aspects of the invention disclosed herein provide methods and compositions that are useful for protecting RNAs from degradation (e.g., exonuclease mediated degradation).Type: ApplicationFiled: April 30, 2015Publication date: August 20, 2015Applicant: RaNA Therapeutics, Inc.Inventor: FATIH OZSOLAK
-
Publication number: 20150232858Abstract: Provided herein are oligonucleotides complementary to euchromatic regions of target genes that are useful for increasing expression of the target genes; related compositions and methods are also provided.Type: ApplicationFiled: April 30, 2015Publication date: August 20, 2015Applicant: RaNA Therapeutics, Inc.Inventor: Fatih Ozsolak
-
Publication number: 20150232846Abstract: Aspects of the invention relate to methods for increasing gene expression in a targeted manner. In some embodiments, methods and compositions are provided that are useful for posttranscriptionally altering protein and/or RNA levels in a targeted manner. Aspects of the invention disclosed herein provide methods and compositions that are useful for protecting RNAs from degradation (e.g., exonuclease mediated degradation).Type: ApplicationFiled: April 30, 2015Publication date: August 20, 2015Applicant: RaNA Therapeutics, Inc.Inventor: FATIH OZSOLAK
-
Publication number: 20150232844Abstract: Aspects of the invention relate to methods for increasing gene expression in a targeted manner. In some embodiments, methods and compositions are provided that are useful for posttranscriptionally altering protein and/or RNA levels in a targeted manner. Aspects of the invention disclosed herein provide methods and compositions that are useful for protecting RNAs from degradation (e.g., exonuclease mediated degradation).Type: ApplicationFiled: April 30, 2015Publication date: August 20, 2015Applicant: RaNA Therapeutics, Inc.Inventor: FATIH OZSOLAK
-
Publication number: 20150232836Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of a target gene. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of a target gene. Methods for modulating expression of a target gene using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of a target gene.Type: ApplicationFiled: May 16, 2013Publication date: August 20, 2015Applicants: RaNA Therapeutics, inc., The General Hospital CorporationInventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
-
Publication number: 20150225715Abstract: Aspects of the invention relate to methods for increasing gene expression in a targeted manner. In some embodiments, methods and compositions are provided that are useful for posttranscriptionally altering protein and/or RNA levels in a targeted manner. Aspects of the invention disclosed herein provide methods and compositions that are useful for protecting RNAs from degradation (e.g., exonuclease mediated degradation).Type: ApplicationFiled: April 30, 2015Publication date: August 13, 2015Applicant: RaNA Therapeutics, Inc.Inventor: FATIH OZSOLAK
-
Publication number: 20150225722Abstract: Provided herein are oligonucleotides that are useful for modulating the heterochromatin state of genes; related compositions and methods are also provided. In some embodiments, methods are provided for treating a disease associated with heterochromatin formation, including diseases associated with repeat expansion within genes.Type: ApplicationFiled: April 29, 2015Publication date: August 13, 2015Applicant: RaNA Therapeutics, Inc.Inventor: Fatih Ozsolak
-
Publication number: 20150218560Abstract: Aspects of the invention provide methods for selecting a candidate oligonucleotide for activating expression of a target gene. Further aspects of the invention provide methods of selecting a set of oligonucleotides that is enriched in oligonucleotides that activate expression of a target gene. Further aspects provide single stranded oligonucleotides that modulate gene expression and compositions and kits comprising the same. Methods for modulating gene expression using the single stranded oligonucleotides are also provided.Type: ApplicationFiled: April 20, 2015Publication date: August 6, 2015Applicants: RaNA Therapeutics, Inc., The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
-
Publication number: 20150191722Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of APOA1 or ABCA1. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of APOA1 or ABCA1. Methods for modulating expression of APOA1 or ABCA1 using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of APOA1 or ABCA1.Type: ApplicationFiled: May 16, 2013Publication date: July 9, 2015Applicants: RaNA Therapeutics, Inc., The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
-
Publication number: 20150159160Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of ATP2A2. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of ATP2A2. Methods for modulating expression of ATP2A2 using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of ATP2A2.Type: ApplicationFiled: May 16, 2013Publication date: June 11, 2015Applicants: RaNA Therapeutics, Inc., The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
-
Publication number: 20150159161Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of PTEN. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of PTEN. Methods for modulating expression of PTEN using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of PTEN.Type: ApplicationFiled: May 16, 2013Publication date: June 11, 2015Applicants: RaNA Therapeutics, Inc., The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
-
Publication number: 20150152410Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of MECP2. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of MECP2. Methods for modulating expression of MECP2 using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of MECP2.Type: ApplicationFiled: May 16, 2013Publication date: June 4, 2015Applicants: RaNA Therapeutics, Inc., The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
-
Publication number: 20150141320Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of a target gene. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of a target gene. Methods for modulating expression of a target gene using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of a target gene.Type: ApplicationFiled: May 16, 2013Publication date: May 21, 2015Applicants: RaNA Therapeutics, Inc., The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
-
Publication number: 20150133528Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of hemoglobin genes (HBB, HBD, HBE1, HBG1 or HBG2). Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of hemoglobin genes. Methods for modulating expression of hemoglobin genes using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of hemoglobin genes.Type: ApplicationFiled: May 16, 2013Publication date: May 14, 2015Applicants: RaNA Therapeutics, Inc., The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
-
Publication number: 20150133362Abstract: Aspects of the invention provide methods for selecting a candidate oligonucleotide for activating expression of a target gene. Further aspects of the invention provide methods of selecting a set of oligonucleotides that is enriched in oligonucleotides that activate expression of a target gene. Further aspects provide single stranded oligonucleotides that modulate gene expression and compositions and kits comprising the same. Methods for modulating gene expression using the single stranded oligonucleotides are also provided.Type: ApplicationFiled: May 16, 2013Publication date: May 14, 2015Applicants: RaNA Therapeutics, Inc., The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
-
Publication number: 20150133529Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of BDNF. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of BDNF. Methods for modulating expression of BDNF using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of BDNF.Type: ApplicationFiled: May 16, 2013Publication date: May 14, 2015Applicants: RaNA Therapeutics, Inc., The General Hospital Corporation d/b/a Massachuset General HospitalInventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
-
Publication number: 20150099791Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of UTRN. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of UTRN. Methods for modulating expression of UTRN using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of UTRN.Type: ApplicationFiled: May 16, 2013Publication date: April 9, 2015Applicants: RaNA Therapeutics, Inc., The General Hospital Corporation d/b/a Massachussetts General HospitalInventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
-
Publication number: 20150050738Abstract: Aspects of the invention relate to methods for increasing gene expression in a targeted manner. In some embodiments, methods and compositions are provided that are useful for posttranscriptionally altering protein and/or RNA levels in a targeted manner. Aspects of the invention disclosed herein provide methods and compositions that are useful for protecting RNAs from degradation (e.g., exonuclease mediated degradation).Type: ApplicationFiled: August 15, 2014Publication date: February 19, 2015Applicant: RaNA Therapeutics, Inc.Inventors: Fatih Ozsolak, Caroline Woo